Jiangsu Hansoh Pharmaceutical Co., Ltd. was established in July, 1995. It has developed into a new pharmaceutical group featuring R&D, manufacture, sales and pharmaceutical investment of drugs. In 2010, over 4000 employees bring Hansoh total revenue of 552 million US dollars. Hansoh has 76 products which cover six therapeutic categories: anticancer, antibiotic, psychotropic, anti-diabetic, gastro-intestinal and cardiovascular area.
 
While achieving great success in domestic market, through direct and active participation, Hansoh is gaining steadily in international market. In 2010, two of Hansoh's main anti-cancer API products have occupied over 15% of the whole international market. Over 30 foreign pharmaceutical companies are sourcing our products.
 
Backed by strong R&D teams, Hansoh Pharm continues to be at the forefront of the life-science industry of China. Each year, Hansoh spends more than 8% of the revenue on the R&D. Till now, Hansoh Pharm has filed more than 80 intellectual properties and 21 of them have been granted. 
 

Always flexible and dynamic, Hansoh's production capacity grows very rapidly. In 2007, a new world-class API manufacturing site was built. In 2011, new finished products manufacturing site will be put into use.
 

With continuous improvement, Hansoh's quality system complies with the strictest regulatory requirements of leading health authorities. It has been inspected and approved by US FDA, Japan PMDA, Korea KFDA, etc. Hansoh can provide USP, EP and JP standard products to different customers all over the world.
 

Hansoh is looking forward to promoting great cooperative relationships with customers from all over the world.